BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
July 09, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Regional Commercial Plans Improved Access for More Than 6 Million Lives During 2Q More Than 90% of Commercial Lives Now Have Access to BELBUCA in the U.S. RALEIGH, N.C., July 09, 2019 (GLOBE...
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Named to the Russell 3000® Index
June 20, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., June 20, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index...
BioElectronics Announces Publication of Study Verifying the Effectiveness of Its ActiPatch Medical Device on Chronic Pain
June 03, 2019 09:31 ET
|
BioElectronics Corporation
FREDERICK, MD, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioElectronics Corporation (OTC PINK: BIEL) www.bielcorp.com, the maker of non-invasive electroceutical devices, is pleased to...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
May 29, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
May 28, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
May 06, 2019 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report First Quarter 2019 Financial Results
April 25, 2019 16:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
April 10, 2019 16:07 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public...
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
April 10, 2019 16:06 ET
|
BioDelivery Sciences International, Inc.
Long-term revenue potential of over $75 million for NME with IP protection through 2031 Leverages existing commercial capabilities to provide a novel treatment option for OIC ...